Immune cells within hematological malignancies, such as acute myeloid leukemia (AML), acute lymphoblast leukemia (ALL), diffuse large B-cell lymphoma, multiple myeloma, and follicular lymphoma, demonstrate increased P-gp expression, contributing to chemotherapy resistance. This evidence concerns the gene PGP and plasma cell myeloma.